Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema

Next Previous
Search
Trial Profile

A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARQ 252 (Primary)
  • Indications Eczema
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arcutis Biotherapeutics

    • Most Recent Events

    • 01 Jul 2021 Results published in the Arcutis Biotherapeutics Media Release.
    • 04 May 2021 Results published in the Arcutis Biotherapeutics financial Media Release.
    • 04 May 2021 Primary endpoint has not been met. (Cohort 2: Investigators Global Assessment (IGA) score of clear or almost clear at Week 12), according to an Arcutis Biotherapeutics financial media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top